Friday, October 27, 2017 10:22:19 AM
https://seekingalpha.com/article/4117162-cytokinetics-cytk-ceo-robert-blum-q3-2017-results-earnings-call-transcript?part=single
1-
If data is available, they will have a big echo chamber to announce the results (hopefully, the positive results). That's only a month and some away! CYTK is optimistic but anything can happen, they need to see the final data of course.
2 -
If those patients did not see any benefits, would they continue on the open-label? Would they be on tirasemtiv for two years?
3 - Lots of updates on other trials to be announced over the course of 2018
4 -
The market will include the 'aging population'! That's, what's the word ..., Huge!
5 -
Strong financial situation + strong partners: They will not be the object of the typical biotech short attacks or if they are, they are very well position to resist those. And they may have enough cash to get to a commercial stage if tirasemtiv is approved, say, late 2018, early 2019. They are in a very good position.
6 - They have a strategy in case tirasemtiv is a failure to reallocate resources to other trials. A failure would be hard for the company, but I like the fact that they are thinking about how to continue in this case. It's rare you hear those plans from a biotech. It also shows the strength of their pipeline!
I like the upcoming catalyst being about a month away, the optimistic note around the Ph III, the cash position, and the pipeline. I bought a few more shares today.
Recent CYTK News
- Cytokinetics to Announce First Quarter Results on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 08:00:00 PM
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress • GlobeNewswire Inc. • 04/10/2024 11:30:00 AM
- Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session • GlobeNewswire Inc. • 04/05/2024 11:30:00 AM
- Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session • GlobeNewswire Inc. • 04/05/2024 11:30:00 AM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 08:00:00 PM
- Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/01/2024 08:00:00 PM
- Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session • GlobeNewswire Inc. • 03/25/2024 12:15:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:26:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:24:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:22:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:18:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 09:21:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:52 PM
- Cytokinetics to Participate in March Investor Conferences • GlobeNewswire Inc. • 03/04/2024 09:00:00 PM
- Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 03/01/2024 11:47:00 PM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 09:00:00 PM
- Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:22 PM
- Cytokinetics Reports Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 02/27/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:04:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:03:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/13/2024 09:11:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:01:39 PM
- Cytokinetics to Announce Fourth Quarter Results on February 27, 2024 • GlobeNewswire Inc. • 02/13/2024 09:00:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM